Natural killer cell alloreactivity in allogeneic hematopoietic transplantation
暂无分享,去创建一个
[1] M. Bennett,et al. PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS , 1971, Journal of Experimental Medicine.
[2] IMMUNOLOGIC MEMORY CELLS OF BONE MARROW ORIGIN , 1972, The Journal of experimental medicine.
[3] W. Murphy,et al. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection , 1987, The Journal of experimental medicine.
[4] H. Ljunggren,et al. In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.
[5] F. Aversa,et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.
[6] J. Dorfman,et al. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. , 1996, Immunity.
[7] M. Martelli,et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.
[8] A. Tosti,et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.
[9] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[10] J. Roberts,et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.
[11] Todd A Fehniger,et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. , 2002, Blood.
[12] Heather G. Shilling,et al. Genetic Control of Human NK Cell Repertoire1 , 2002, The Journal of Immunology.
[13] NK cells: a lesson from mismatched hematopoietic transplantation. , 2002 .
[14] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[15] Daniel J Weisdorf,et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.
[16] R. Handgretinger,et al. T‐cell alloreactivity dominates natural killer cell alloreactivity in minimally T‐cell‐depleted HLA‐non‐identical paediatric bone marrow transplantation , 2003, British journal of haematology.
[17] P. Parham,et al. The Protein Made from a Common Allele of KIR3DL1 (3DL1*004) Is Poorly Expressed at Cell Surfaces due to Substitution at Positions 86 in Ig Domain 0 and 182 in Ig Domain 1 1 , 2003, The Journal of Immunology.
[18] Franco Locatelli,et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.
[19] J. Luhm,et al. NK cells: a lesson from mismatched hematopoietic transplantation. , 2003, Trends in immunology.
[20] G. Ehninger,et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. , 2004, Blood.
[21] J. P. McCoy,et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. , 2004, Blood.
[22] R. Biassoni,et al. Structure of the Ly49 family of natural killer (NK) cell receptors and their interaction with MHC class I molecules , 2004, Immunologic research.
[23] The Immune System in Graft-vs.-Host Disease: Target and Effector Organ , 2004 .
[24] J. Cahn. Clinical bone marrow and blood stem cell transplantation , 2004, Leukemia.
[25] L. Lanier,et al. Function of NKG2D in natural killer cell–mediated rejection of mouse bone marrow grafts , 2005, Nature Immunology.
[26] D. Campana,et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.
[27] N. Kröger,et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma , 2005, British journal of haematology.
[28] C. Mecucci,et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Velardi,et al. Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors , 2007 .